These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30575417)

  • 1. Discovery of Natural Steroid 5 Alpha-Reductase Inhibitors.
    Srivilai J; Minale G; Scholfield CN; Ingkaninan K
    Assay Drug Dev Technol; 2019; 17(2):44-57. PubMed ID: 30575417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new label-free screen for steroid 5α-reductase inhibitors using LC-MS.
    Srivilai J; Rabgay K; Khorana N; Waranuch N; Nuengchamnong N; Ingkaninan K
    Steroids; 2016 Dec; 116():67-75. PubMed ID: 27789379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.
    Cabeza M; Sánchez-Márquez A; Garrido M; Silva A; Bratoeff E
    Curr Med Chem; 2016; 23(8):792-815. PubMed ID: 26861003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia.
    Sun J; Xiang H; Yang LL; Chen JB
    Curr Med Chem; 2011; 18(23):3576-89. PubMed ID: 21756226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders.
    Paba S; Frau R; Godar SC; Devoto P; Marrosu F; Bortolato M
    Curr Pharm Des; 2011; 17(2):151-67. PubMed ID: 21361868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols.
    Hiipakka RA; Zhang HZ; Dai W; Dai Q; Liao S
    Biochem Pharmacol; 2002 Mar; 63(6):1165-76. PubMed ID: 11931850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G; Rittmaster RS; Klocker H
    Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.
    Issa S; Schnabel D; Feix M; Wolf L; Schaefer HE; Russell DW; Schweikert HU
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5401-7. PubMed ID: 12466325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The enzyme and inhibitors of 4-ene-3-oxosteroid 5 alpha-oxidoreductase.
    Li X; Chen C; Singh SM; Labrie F; Labire F [corrected to Labrie F]
    Steroids; 1995 Jun; 60(6):430-41. PubMed ID: 7676475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
    Pais P
    Adv Ther; 2010 Aug; 27(8):555-63. PubMed ID: 20623347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
    Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
    J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory activities of Puerariae Flos against testosterone 5α-reductase and its hair growth promotion activities.
    Murata K; Noguchi K; Kondo M; Onishi M; Watanabe N; Okamura K; Matsuda H
    J Nat Med; 2012 Jan; 66(1):158-65. PubMed ID: 21822606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Liquid Chromatography/Mass Spectrometry-Based Inhibition Assay for the Screening of Steroid 5-α Reductase in Human and Fish Cell Lines.
    Kim D; Cho H; Eggers R; Kim SK; Ryu CS; Kim YJ
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33567691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
    Hirsch KS; Jones CD; Audia JE; Andersson S; McQuaid L; Stamm NB; Neubauer BL; Pennington P; Toomey RE; Russell DW
    Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5277-81. PubMed ID: 8389478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid 5alpha-reductase inhibitors.
    Flores E; Bratoeff E; Cabeza M; Ramirez E; Quiroz A; Heuze I
    Mini Rev Med Chem; 2003 May; 3(3):225-37. PubMed ID: 12570838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
    Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
    J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
    Lao K; Sun J; Wang C; Wang Y; You Q; Xiao H; Xiang H
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4212-4217. PubMed ID: 28757062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.